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G protein-coupled receptors (GPCRs) constitute a superfamily of cell-surface receptors which share a common topology of seven
transmembrane domains and modulate a variety of cell functions through coupling to heterotrimeric G proteins by responding to a vast array of
stimuli. The magnitude of cellular response elicited by a given signal is dictated by the level of GPCR expression at the plasma membrane, which
is the balance of elaborately regulated endocytic and exocytic trafficking. This review will cover recent advances in understanding the molecular
mechanism underlying anterograde transport of the newly synthesized GPCRs from the endoplasmic reticulum (ER) through the Golgi to the
plasma membrane. We will focus on recently identified motifs involved in GPCR exit from the ER and the Golgi, GPCR folding in the ER and the
rescue of misfolded receptors from within, GPCR-interacting proteins that modulate receptor cell-surface targeting, pathways that mediate GPCR
traffic, and the functional role of export in controlling GPCR signaling.
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GPCRs are a superfamily of cell-surface receptors which
modulate a variety of cell functions through coupling to
heterotrimeric G-proteins and regulating downstream effectors
such as adenylyl cyclases, phospholipases, protein kinases and
ion channels [1–6]. All GPCRs share a common molecular
topology with a hydrophobic core of seven transmembrane-
spanning α-helices, three intracellular loops, three extracellular
loops, an N-terminus outside the cell, and a C-terminus inside
the cell. The life of GPCRs begins at the ER where they are
synthesized, folded and assembled. Properly folded receptors
are recruited and packaged into ER-derived COPII-coated
vesicles. Transport vesicles carrying cargo receptors then
migrate from the ER to the ER–Golgi intermediate complex
(ERGIC), the Golgi apparatus and the trans-Golgi network
(TGN). During their migration, receptors undergo post-transla-
tional modifications (e.g. glycosylation) to attain mature status.
Mature receptors then move from the TGN to their functional
destination at the plasma membrane [7]. Upon stimulation by
their ligands, GPCRs at the plasma membrane may undergo
internalization which involves phosphorylation of the receptors
by G protein receptor kinases, and subsequent binding of
phosphorylated receptors to arrestins. Arrestins function as
adaptor proteins recruiting components of the transport
machinery to the clathrin-coated pits and initiating formationof the early endosome. Internalized receptors in the endosome
are sorted to the recycling endosome for return to the plasma
membrane or to the lysosome for degradation [3–6]. The
balance of these dynamic intracellular trafficking (i.e. export,
endocytosis and degradation) dictates the level of receptor
expression at the plasma membrane, which in turn influences
the magnitude of the cellular response to a given signal.
Compared with the extensive studies on the events of the
endocytic pathway [3–6], molecular mechanisms underlying
the transport processes of GPCRs from the ER to the cell
surface and the regulation of receptor signaling by these
processes are relatively less well understood. The progress
achieved over the past few years indicates that GPCR export
from the ER and the Golgi and targeting to the cell surface are
highly regulated processes. This review will focus on five
aspects related to GPCR export trafficking: (1) identification of
conserved sequences/motifs in GPCRs essential for their exit
from the ER and the Golgi and their retention in the ER; (2)
GPCR folding in the ER and rescue of intracellularly retained
GPCRs; (3) regulatory role of GPCR-associated proteins in
GPCR export trafficking; (4) distinct pathways directing
GPCRs to the cell surface; and (5) control of GPCR signaling
by anterograde traffic along the secretory pathway. The role of
dimerization (homo- and hetero-dimerization) between GPCRs
in controlling their folding status and intracellular trafficking is
reviewed by Dr. Milligan in this series.
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2.1. C-terminal motifs involved in ER export
Export from the ER represents the first step in intracellular
trafficking of GPCRs and is a dynamic and highly regulated
event in the biogenesis of GPCRs. The efficiency of ER export
has a marked effect on the kinetics of GPCR maturation and
cell-surface targeting. Indeed, export from the ER has been
shown to be the rate-limiting step in the biogenesis of the δ-
opioid receptor (DOR) [8]. Hebert's group has recently
demonstrated that GABAB1 receptor, G protein βγ subunits
and the inwardly rectifying potassium channel Kir 3 form a
signaling complex shortly after biosynthesis and the formation
of the complex occurs most likely in the ER [9,10]. Protein
transport from the ER is exclusively mediated through the
COPII-coated vesicles. In order to be efficiently exported in
COPII vesicles, cargo proteins, particularly transmembrane
proteins, may specifically bind to the components of COPII
vesicles. The interaction is mediated by ER export signals
presented in the C-termini of transmembrane cargoes that are
accessible to binding sites on the luminal face of the Sar1 and
Sec23/24 complex [11–24].
The ER export signals characterized in non-GPCR
membrane proteins to date are divided into two classes. The
diacidic motif, DXE, has been identified in the cytoplasmic
C-termini of the vesicular stomatitis viral glycoprotein
(VSVG), cystic fibrosis transmembrane conductance regulator
(CFTR) and Kir2.1 potassium channel [12–15]. The DXE
motif directs the concentration of the cargo molecule during
export from the ER thereby enhancing the rate of its exit from
the ER. Mutation of the DXE motif to AXA results in a
VSVG molecule which assembles correctly but exits the ER
at a ∼10-fold slower rate [12,13]. The DXE motif also con-
fers its transport ability to sufficiently direct the export of
other proteins, which are normally retained in the ER [12].
More specifically, the motif is required for the interaction of
VSVG with Sec23/24 in a ternary pre-budding complex
consisting of Sar1-GTP, cargo, and Sec23/24. The DXE motif
has also been found in the yeast membrane proteins Sys1p
and Gap1p and mediates their interaction with Sar1 and
Sec23/24 [16,17]. Interestingly, in addition to interacting with
COPII to facilitate transport from the ER, the DXE motif in
VSVG also interacts with adaptor protein-3 to achieve
efficient transport from the TGN to the cell surface [18],
indicating that a single sorting sequence can interact with
sequential coat machineries to direct transport through the
exocytic pathway. Similarly, a second class of ER export
signal, the dihydrophobic motif is required for efficient
transport of the ERGIC-53, p24 family of proteins, and the
Erv41–Erv46 complex from the ER to the Golgi [19–23].
Like DXE, the double phenylalanine motif (FF) was shown to
participate in the binding of Sec23/24 [22]. Mutation of the
motif to alanines abolishes such interaction and results in
redistribution of the protein to the ER. Consistent with the
idea that different ER-export motifs interact with the sameCOPII components to facilitate ER export, multiple binding
sites on the Sec23 molecule have been identified for distinct
cargo molecules [24].
Efforts to define structural determinants of GPCR export
from the ER have continually led researchers to the C-terminal
tails. The requirement of the C-terminus, particularly the
membrane-proximal portion, for ER export has been demon-
strated for a number of GPCRs including rhodopsin, vaso-
pressin V2 (V2R), dopamine D1 (D1R), adenosine A1 (A1AR),
α2B-adrenergic (α2B-AR), angiotensin II type 1 (AT1R), mela-
nin-concentrating hormone receptor 1 and luteinizing hor-
mone/choriogonadotropin receptors [25–31]. For instance,
progressive truncation of the C-terminus from AT1R does
not have an effect on receptor transport until the membrane-
proximal region is disturbed [29]. Mutagenesis studies of the
membrane-proximal C-termini have led to the identification of
several motifs that play a critical role in GPCR export from the
ER.
2.1.1. E(X)3LL motif
The dileucine (LL) motif in the membrane-proximal
C-termini of GPCRs has been demonstrated to function as a
sorting signal at the TGN for basolateral cell-surface transport
and as a mediator of endocytosis into clathrin-coated vesicles
through interacting directly with the clathrin adaptor protein
complex at the plasma membrane [32,33]. In addition, the LL
motif (DSLL) at the end of the β2-AR C-terminus regulates
recycling of internalized receptors [34], and the LL motif within
the third intracellular (i3) loop of opioid receptors is involved in
regulation of receptor targeting to the lysosome [35]. Schulein et
al. demonstrated that the LL motif together with an upstream
glutamate (E) residue [E(X)3LL] in the C-terminus of V2R is
essential for receptor cell-surface expression [36]. Mutation of
the glutamate and leucine residues individually or in combina-
tion markedly inhibits receptor expression at the cell surface and
traps receptors within the ER.
2.1.2. F(X)3F(X)3F motif
A triple phenylalanine motif [F(X)3F(X)3F] has been
identified in the membrane-proximal C-terminus of the D1R
that is required for receptor cell-surface expression [37].
Mutation of the three phenylalanines results in a complete
loss of cell-surface localization, with an intracellular distribu-
tion pattern that overlaps with an ER specific marker. Moreover,
the mutant receptor is incapable of triggering cAMP production
in response to dopamine stimulation.
2.1.3. FN(X)2LL(X)3L motif
Robert et al. demonstrated that a dileucine and surround-
ing hydrophobic residues, namely upstream phenylalanine
and asparagine and downstream leucine, constitute an ER
export motif [FN(X)2LL(X)3L] within the membrane-proxi-
mal C-terminus of the human vasopressin V1b/V3 receptor.
Mutation of one or more of these five residues within this motif
attenuates receptor expression at the plasma membrane,
indicating that these residues are required for receptor export
from the ER [38].
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We demonstrated that the C-termini of α2B-AR and AT1R are
required for their expression at the cell surface [29]. Receptor
mutants lacking the C-termini are unable to exit from the ER as
indicated by extensive co-localization with the ER marker
calregulin. Utilizing strategies of progressive truncation and
alanine-scanning mutagenesis, we found that F436 and I443L444
in the C-terminus of α2B-AR and F
309 and L316L317 in the C-
terminus of AT1R are required for receptor export from the ER
[29]. Mutant receptors are arrested in the ER and unable to
initiate downstream signaling. These data suggest the existence
of an ER export motif consisting of a phenylalanine and double
leucine spaced by six residues [F(X)6LL, where X can be any
residue and L is leucine or isoleucine]. More recent studies have
demonstrated that the F(X)6LL motif is also essential for ER
export of β2-AR and α1B-AR (unpublished observation). More
interestingly, insertion or deletion of one or two residues
between F436 and I443L444 in the α2B-AR abolishes ER export,
suggesting that the spatial juxtaposition of the residues F436 and
I443L444 in the F(X)6LL motif is crucial to their function.
Furthermore, we have shown that mutation of I443L444 to FF, a
well-known ER export motif, also markedly attenuates transport
of the receptor to the cell surface. We have also found that
mutation of I443L444 to a double valine (VV), which has a very
similar hydrophobic index to leucine but a slightly different pre-
sentation of methyl groups on the side chain, severely abrogates
ER export of the receptor (unpublished observation). These data
suggest that the precise structure of the double leucine residues is
vital to its function in mediating receptor export from the ER. As
the F(X)6LL motif is highly conserved in the membrane-
proximal C-termini of GPCRs [29], the F(X)6LL motif may
provide a common mechanism for ER export of GPCRs.
2.2. N-terminal motifs involved in GPCR export
2.2.1. The role of the extracellular N-termini in GPCR export
trafficking
Studies of intrinsic structural determinants for GPCR export
trafficking have been mainly focused on the C-termini of the
receptors. The roles of the N-termini in regulating GPCR
export trafficking have been much less investigated and remain
controversial. For instance, whereas proteolytical cleavage of
the N-terminal 64 amino acid residues reduces the expression
of the endothelin B receptor at the cell surface, removal of the
N-terminus facilitates α1D-AR cell-surface transport, but has
no influence on α1B-AR anterograde trafficking [39,40]. We
have determined the role of the N-termini in the export of α2-
ARs from the ER through the Golgi to the cell surface. Our
data demonstrated that, similar to the intracellular C-terminus,
the extracellular N-terminus is also essential for cell-surface
targeting of α2B-AR. An α2B-AR mutant lacking the N-
terminal 12 residues is completely unable to transport to the
cell surface and is extensively trapped in the ER [41]. These
data, together with our previous data, strongly indicate that
both extracellular and intracellular terminal tails of α2B-AR
contain structural determinants for its targeting to the cell
surface.2.2.2. N-terminal motifs required for export from the Golgi
Protein export from the Golgi to the cell surface is
conventionally considered as a constitutive process. However,
several studies have indicated that protein export from the Golgi
may be mediated through highly specific motifs. For example,
VSVG uses the tyrosine-based di-acidic motif (YTDIE) in the
C-terminus to recruit adaptor protein complex 3 and facilitate its
transport from the TGN to the cell surface [18]. Moreover,
cytoplasmic N-terminal positively charged residues are neces-
sary for the efficient export of inward rectifier potassium
channels from the Golgi complex [42]. For GPCRs, olfactory
and chemokine receptors have been reported to be released from
the ER, but accumulate in the Golgi [43,44]. It has been recently
demonstrated that E150K, a missense opsin mutation associated
with autosomal recessive retinitis pigmentosa, is able to
transport to the cis- and medial-Golgi compartments, but not
the trans-Golgi compartment [45]. These studies suggest that,
similar to ER export, GPCR exit from the Golgi is a regulatory
process. However, the specific sequences for GPCR exit from
the Golgi have not yet been identified.
Our recent studies have identified the first motif, consisting
of a tyrosine and a serine (YS), which is crucial for α2-AR
export from the Golgi. Alanine substitution of the YS motif
individually or in combination within α2A-AR and α2B-AR
markedly arrests the receptor in the Golgi [41]. The YS motif is
highly conserved in the membrane-proximal N-termini of α2A-,
α2B- and α2C-AR subtypes in different species. Therefore, the
YS motif in the N-terminal portion may provide a common
mechanism for the Golgi export of this subgroup of adrenergic
receptors.
The YS motif identified in the membrane-proximal N-
termini of α2-ARs is apparently different from other Tyr-based
signals, which have been demonstrated to modulate intracellular
trafficking at distinct steps of a variety of proteins including
GPCRs [46]. The NPXY motif functions as an internalization
signal for non-GPCRs [47,48]. NPXXY motif, which is highly
conserved in many GPCRs within the putative seventh
transmembrane domain near the cytoplasmic face of the plasma
membrane, is involved in the endocytic trafficking of the
receptors [49–51]. The Tyr-based sorting motif YXXΦ (where
Φ has a bulky hydrophobic side chain) facilitates protein
transport from the TGN to the lysosome or basolateral
membranes in polarized cells [52–55]. Therefore, the YS
motif may represent a novel Tyr-based motif which is required
for the transport of α2-AR from the Golgi to the cell surface.
2.2.3. The role of N-linked glycosylation in GPCR export to the
cell surface
N-linked glycosylation at the consensus sequence NXS/T is
the most common post-translational modification of GPCRs. The
role of N-linked glycosylation in modulating GPCR targeting to
the cell surface differ among GPCRs. N-linked glycosylation of
AT1R and follicle-stimulating hormone receptor (FSHR) is
absolutely required for the cell-surface expression of the
receptors, as mutation of the glycosylation sites abolishes
receptor transport to the plasma membrane and causes an
accumulation of mutated receptors in the perinuclear region
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its transport to the cell surface, as mutation of N-linked
glycosylation sites is accompanied by a marked reduction in
plasma membrane expression of the receptors [59]. In contrast,
N-linked glycosylation of α1-AR, H2 histamine and M2-
muscarinic receptors (M2-MR) has no significant influence on
their expression at the cell surface [60–62].
2.3. Mechanism of motif-mediated export from the ER and the
Golgi
The motifs discussed above have been demonstrated to be
required for GPCR export trafficking. However, the molecular
mechanism underlying their function remains unclear. There are
several possibilities regarding the role of the motifs in GPCR
export from the ER. First, similar to the DXE and FF motifs,
these motifs may function as independent ER export signals,
autonomously directing receptor export from the ER. Consistent
with this possibility, the F(X)3F(X)3F, FN(X)2LL(X)3L and F
(X)6LL motifs have been demonstrated to be able to confer their
transport capabilities to some ER-retained proteins (i. e. the
amino portion of CD8 molecule and AT1R mutant lacking the
C-terminus). However, unlike the DXE and FF motifs, there is
no evidence that any of these motifs directly associate with the
components of the COPII vesicles. Second, the motifs may be
involved in proper receptor folding in the ER. Indeed, mutations
of these motifs severely impair ligand binding of the receptors.
In addition, the F(X)3F(X)3F motif mediates the interaction of
D1R with the ER chaperone protein DRiP78 [37]. However,
whether these motifs are indeed involved in correct receptor
folding in the ER needs additional proof, such as functional
measurement of purified ER-retained receptor mutants and
measurement of receptor conformation by circular dichroism.
Third, the motifs may be involved in receptor dimerization,
which is required for export from the ER of some GPCRs.
However, our studies have demonstrated that an α2B-AR
mutant, in which the F(X)6LL motif is mutated, retains its
ability to form homodimers and heterodimers with wild-type
α2B-AR, suggesting that the F(X)6LL motif is not involved in
receptor dimerization [63].
The YS motif within the N-terminus of α2-AR is positioned
towards the lumen of the ER or the Golgi during the export
process. Thus, this motif is unable to directly interact with
components of the transport machinery or other proteins in the
cytoplasm, and unlikely functions as a linear independent export
signal directing α2-AR exit from the Golgi. Furthermore, the YS
mutant exits from the ER and reaches the Golgi, suggesting the
mutant receptor is correctly folded to pass the ER quality control
mechanism. Therefore, the molecular mechanism underlying the
function of the YS motif in mediating α2-AR export is different
from those proposed for the export motifs identified in the C-
termini of receptors and other membrane proteins.
2.4. ER retention motifs of GPCRs
Even correctly folded proteins may be retained in the ER
because they contain ER retention motifs preventing theirexport from the ER. There are three types of ER retention motifs
identified in the cytosolic domains of various proteins: the
KDEL, KKXX and RXR motifs. The KDEL motif was
identified in ER luminal chaperone proteins such as BiP and
protein disulfide isomerase. The dilysine KKXX motif was
identified in type I integral membrane proteins [64–66]. Both
the KDEL and KKXX motifs are believed to function as
retrieval signals recycling proteins from the Golgi back to the
ER [67,68]. In contrast, the RXR motif, which was first
identified in ion channels, actively precludes the exit of proteins
from the ER [69,70]. This type of motif has been found in
several GPCRs.
The RSRR motif was identified in the C-terminus of the
gamma-aminobutyric acid type B1 receptor (GABABR1) as
an ER retention motif [71,72]. When expressed alone, the
GABABR1 is retained in the ER. Only when co-expressed
with its partner GABABR2, GABABR1 is released from the
ER and transports to the cell surface. Upon co-expression,
heterodimerization of the two receptors mediated by their
C-terminal tails masks the RXR-based retention signal pre-
sented in GABABR1 thereby allowing its export from the
ER [72]. The GABABR1 may also be artificially transported
from the ER by mutation or deletion of the RSRR motif.
Interestingly, the function of the RSRR motif is sensitive to
the length of the space between the motif and the receptor's
membrane anchor [73]. For instance, the function of the
RSRR motif is attenuated by being transferred from the
C-terminus to the i3 loop. In contrast, this motif remains
functional when its position is altered within the distal re-
gion of the C-terminus [73]. Therefore, proper operation of
the ER retention motif requires exact positioning in the
appropriate context.
As compared with the C-terminally localized ER retention
motifs, the i3 loop of V2R contains an arginine-rich sequence,
RRRGRR encompassing two overlapping RXR motifs [74]. A
V2R mutant containing the first transmembrane domain, the
first intracellular loop and the N-terminus is able to express at
the cell surface. Addition of the i3 loop to this mutant inhibits its
expression at the cell surface, presumably due to the presenta-
tion of the RXR based retention motif [74]. This inhibitory
effect can be released by mutating the arginine residues to
lysines in the RRRGRR motif in the i3 loop [74,75]. The fact
that the wild-type V2R transports to the cell surface without
significant accumulation in the ER suggests that the ER re-
tention motif in the i3 loop is masked under normal conditions.
These data, together with the data obtained from GABABR,
suggest that the ER retention signals in some GPCRs may act as
mediators of the quality control system, functioning only when
the receptor is incompletely folded or assembled.
In contrast to GABABR and V2R which harbor the RXR
motif, Chan et al. identified the sequence RRKK within the C-
termini of metabotropic glutamate receptor (mGluR) 1a and 1b
to be an ER retention signal [76]. The presence of this motif is
responsible for the reduced cell-surface expression of mGluR1b
as its removal increases the cell-surface expression and
dendritic trafficking of mGluR1b. However, the function of
this ER retention signal in mGluR1a is overridden by other
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membrane expression of mGluR1a [76].
3. GPCR folding in the ER and rescue of misfolded GPCRs
3.1. ER quality control
Proteins must attain their native conformation in order to
exit from the ER. Incompletely or misfolded proteins are
excluded from the ER-derived transport vesicles by means of
an ER quality control mechanism [77]. The ER quality control
mechanism refers to the ER's ability to recognize non-native
conformations in proteins and prevent their export and
potentially lethal presence within the cell. Such fidelity in
protein production relies on the integrated network of ER
resident chaperones and folding factors which bind exposed
hydrophobic surfaces, unpaired cysteines, and immature
glycans of incompletely folded proteins. These interactions
prevent the aggregation of folding intermediates and at the
same time facilitate proper folding by stabilizing sequential
conformations along the folding pathway as the newly
synthesized peptide is passed from one chaperone to the next.
Only when a protein has assumed its native conformation it is
released from the chaperone to become available for recruit-
ment into the transport vesicles leaving the ER. In the event that
a protein is not folded into its proper conformation, molecular
chaperones will remain bound to the misfolded protein and
prevent its export from the ER. Chaperone-bound misfolded
proteins are covalently ubiquitinated and then targeted for
degradation by the process known as ER-associated degrada-
tion (ERAD) [78]. Similar to other membrane proteins, GPCRs
have to be correctly folded in order to pass through the ER
quality control. Incompletely folded or misfolded receptors
cannot pass the ER quality control mechanism and are targeted
for degradation. Recent studies have demonstrated that some
GPCRs such as bradykinin type 1 receptor (B1R), thyrotropin-
releasing hormone receptor, olfactory receptor mOREG, and
rhodopsin are ubiquitinated and degraded without reaching the
plasma membrane [79–82].
Recent studies have shown that certain proteins, by default,
may be exported from the ER in a more inefficient manner so
as to gain more precise control over expression levels at their
functional destination. At any given time, there exists in the
ER a balance between incompletely folded protein that is
sterically retained by the ER quality control system and fully
folded proteins that are shuffled out of the ER. These
incompletely folded proteins are recognized by the quality
control system via small anomalies in conformations that may
or may not affect its function. Therefore, the balance could
easily be tipped in favor of more ER retention and a slower
rate of export by mutations that would destabilize the protein
conformation. In fact, many GPCRs are inefficiently expressed
at the plasma membrane and only a small fraction of the total
amount of receptor synthesized in the ER actually can be
exported out of the ER. Such restricted trafficking provides the
cell with a pool of functional receptor that can be called upon
immediately by relaxing the scrutiny of the quality controlsystem or stabilizing receptor conformation. Perhaps the best
example of this concept is the gonadotropin releasing hormone
receptor (GnRHR), the primary mediator of neuro-endocrine
integration for the reproductive system [83]. For instance,
catfish GnRHR is robustly expressed at the plasma membrane,
whereas human GnRHR is inefficiently exported to the plasma
membrane. The cell-surface transport efficiency is likely linked
to a 50 residue C-terminal tail that is present in the catfish
GnRHR but not in the human GnRHR [84]. In addition, the
human GnRHR has an extra Lys residue at position 191, which
is absent in the rat and mouse GnRHR. Lys191 appears to
destabilize protein conformation by inhibiting the formation of
intra-molecular cystein bonds [85]. Genetic manipulation of
GnRHR has been demonstrated to successfully restore the cell-
surface targeting of GnRHR. The tethering of the C-terminal
portion of the catfish GnRHR to the rat GnRHR significantly
facilitates receptor expression at the cell surface [84].
Furthermore, the human GnRHR expression at the plasma
membrane can be promoted by genetically deleting a primate-
specific Lys191. Interestingly, the rescue effect of the
combination of adding the catfish GnRHR C-terminus to and
removing Lys191 from the human GnRHR is greater than
additive [86]. This difference in intrinsic stability is also
illustrated by the fact that plasma membrane expression of
human but not rat GnRHR is enhanced by receptor
antagonists that presumably stabilize receptor conformation
(see chapter 3.3). It also explains why the trafficking of the
human GnRHR is so susceptible to point mutations, the very
mutations which have little or no effect on the trafficking of
rat or mouse GnRHR [83].
3.2. GPCR interaction with ER chaperone proteins
Chaperone interaction with GPCRs plays a crucial role for
the ER quality control and ERAD in the biosynthesis of GPCRs
and modulates the availability of functional receptors at the
plasma membrane. Indeed, the largest group of proteins
interacting with GPCRs and regulating their trafficking is the
ER chaperone proteins. The best characterized ER chaperone
proteins interacting with GPCRs are calnexin, calreticulin and
BiP [87,88]. The ER chaperones, as they do for other proteins,
appear to have a dual function for GPCRs not only promoting
proper folding of the immature receptors, but also preventing
the transport of terminally misfolded receptors from the ER to
the Golgi.
Calnexin and calreticulin have been demonstrated to interact
with several GPCRs including AT1R, V2R, V3R, luteinizing
hormone receptor (LHR), FSHR, thyrotropin receptor, melanin
concentrating hormone receptor 1 (MCHR1) and the mouse
ordorant receptor mI7 [81,89–95]. Calnexin and calreticulin
are lectin-like chaperone proteins which recognize and bind
to early oligosaccharide intermediates on the folding
glycoprotein and have been suggested to facilitate the folding
and maturation of glycoproteins through the N-linked glycans
[77,87,88]. However, the non-glycosylated AT1R is able to
associate with calnexin [89]. Furthermore, the interaction
between LHR and calnexin cannot be totally disrupted by
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lated oligosaccharides [93], suggesting that the N-linked
glycosylation of GPCRs is not the only determinant for their
interaction with the ER chaperones. Indeed, mutation of N-
glycosylation sites in some GPCRs does not significantly
alter their targeting to the cell surface as discussed in the
Section 2.2.3.
BiP (also called Grp78) is a heat shock protein that
recognizes and binds hydrophobic patches in unfolded poly-
peptides assisting the folding of newly-synthesized proteins
[96]. BiP is also essential for translocation of the newly
synthesized peptides into the ER and retrotranslocation of
misfolded protein back across the membrane during ERAD
[96]. It has been demonstrated that BiP interacts with several
GPCRs such as AT1R, rhodopsin, thyrotropin receptor and
LHR [93,94,97,98]. In addition, another heat shock protein
Grp94 has also been shown to interact with GPCRs, such as
LHR and rhodopsin mutants [93,98].
It has been well demonstrated that chaperone interaction
with the misfolded and unglycosylated receptors is more stable
than with the wild-type receptors. As the sensors of protein
misfolding, an enhanced interaction of mutated receptors with
the ER chaperones would suggest a folding problem in the
receptors. For example, BiP binds more persistently to the ER-
retained misfolded LHR mutants (A593P and S616Y) [93].
Interaction of calnexin with several ER export-deficient GPCR
mutants (such as V2R–R337X and MCHR1–T255A) is much
stronger than with wild-type counterparts [90,95]. In addition,
the interaction between GPCRs and the ER chaperones exhibits
certain specificity. For example, the ER-localized mouse
olfactory receptor mI7 preferentially interacts with calnexin
compared with calreticulin [81]. It has also been demonstrated
that different mutants of the same GPCR exhibit differential
interaction with the ER chaperone proteins. For instance,
Grp94 interacts with the LHR mutant A593P, but not S616Y
under the same experimental condition, which most likely
reflects the different folding statuses of the mutated receptors
[93].
3.3. Rescue of misfolded GPCRs by chemical and
pharmacological chaperones
Most loss-of-function GPCR mutants are caused by their
misfolding, resulting in intracellular retention and a reduction inTable 1
Rescue of GPCRs by chemical and pharmacological chaperones and reduced tempe
GPCRs Treatments Readouts
V2R DMSO, glycerol, TMAO, Ca
2+ agents Glycosylation, cel
SR121463,VPA-985
Low temperature
V3R SSR149415 Glycosylation, cel
GnRHR Indole antagonists Cell-surface expre
Rhodopsin 11-cis-7-ring-retinal, 9-cis-retinal, 11-cis-retinal, Glycosylation, cel
DOR Naltrexone, TICP(ψ), buprenophine Glycosylation, cel
B1R DMSO, glycerol Glycosylation, cel
Compound 11
α2C-AR Low temperature Cell-surface exprethe plasma membrane expression of the receptors, a conse-
quence which has been thought to be at the root of many
hereditary diseases [99–103]. Over the past several years,
restoration of disease-causing misfolded GPCR mutant expres-
sion at the plasma membrane and functional response has been a
hot topic. Successful rescue of misfolded GPCRs can be
achieved by many means such as chemical chaperones,
pharmacological chaperones, lowering temperature and genetic
approaches (Table 1). Chemical chaperones, including osmo-
lytes (glycerol, sorbitol, DMSO), amino acids (glycine, taurine),
methylamines (betaine, trimethylamine N-oxide) and SERCA
pump inhibitors (thapsigargin, cucurmin), have been shown to
diminish the function of ER resident chaperones thereby
discouraging their interaction with misfolded proteins. Pharma-
cological chaperones (or “pharmacoperones), on the other hand,
are cell permeable receptor ligands, which stabilize the
conformation of misfolded receptors for long enough to evade
the scrutiny of the ER resident chaperones thereby promoting
their export from the intracellular compartments in which they
have accumulated.
The most successfully rescued GPCRs are the V2R mutants
[104–107]. There are over 150 mutants of V2R, which are
associated with symptoms of nephrogenic diabetes insipidus
[102]. Over 70% of these mutants are not expressed at the cell
surface, but accumulate in the intracellular compartments. Their
ability to be rescued varies according to the particular mutant
concerned and the treatment being employed. Chemical
chaperones, including glycerol, DMSO, thapsigargin/curcumin,
and ionomycin, are able to rescue the V2R mutant V206D
which has only a minor folding defect [107]. Selective cell
permeable non-peptide V2R antagonists such as SR121463,
VPA-985 and SR49059, act as pharmacological chaperones
dramatically enhancing the expression of some V2R mutants at
the plasma membrane and restoring their abilities to bind ligand
and activate cellular responses. Additionally, treatment with
SSR149415, a non-peptide V3R antagonist, promotes the
plasma membrane transport of the V3R mutant, which is
defective in ER export due to mutation of the hydrophobic motif
FN(X)2LL(X)3L in the C terminus as discussed above. Once at
the plasma membrane, the V3R mutant functions normally as
wild-type V3R [91].
Another excellent example of GPCR mutant rescue is
GnRHR. There are 13 naturally occurring mutations in
GnRHR which impair export ability and are associated withrature
References
l-surface expression, cAMP production, chloride conductance [104–107]
l-surface expression, calnexin interaction, IP3 production [91]
ssion, IP production [108–110]
l-surface expression [112,113]
l-surface expression [114]
l-surface expression, arachidonate release [79]
ssion, cAMP production, smooth muscle contractility [115,116,119]
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that treatment with specific GnRHR antagonists restores the
plasma membrane traffic and biological function of these
mutants [108–110]. For example, the GnRHR mutants T32I,
E90K, C200Y, C279Yand L266R, widely distributed within the
GnRHR, are rescued at varying degrees, when transiently
expressed in COS7 cells and treated with IN3, a small molecule,
nonpeptide antagonist. The IN3 treatment increases the cell-
surface expression of the receptor as measured by ligand
binding and augments functional response by agonist-mediated
inositol phosphate production [109].
Similarly, pharmacological chaperones facilitate the cell-
surface targeting of intracellularly accumulated rhodopsin
mutants which are associated with the inherited disease retinitis
pigmentosa, the most common form of hereditary retinal
degeneration [101]. The most frequent mutation (∼10% of the
cases) is P23H which accumulates in the ER [111]. Treatment
with three different cell permeable agonists, 11-cis-7-ring-
retinal and 9- and 11-cis-retinal increases the plasma membrane
expression of P23H by 3.5 times [112,113].
In addition to the misfolded GPCR mutants, chemical and
pharmacological chaperones are also able to promote the
maturation and cell-surface targeting of wild-type GPCRs. For
instance, wild-type DOR inefficiently targets to the plasma
membrane. Treatment with naltrexone, a non-selective opioid
receptor antagonist, promotes the maturation of DOR in stably
transfected HEK293T cells [114]. B1R localizes mostly in the
ER and the Golgi and is constitutively targeted to proteasomes
for degradation. Treatment with chemical or pharmacological
chaperones promotes the formation of highly glycosylated B1R
and its subsequent targeting to the cell surface [79].
3.4. Rescue of intracellularly retained GPCRs by lowering
temperature
In addition to chemical and pharmacological chaperones,
lowering temperature has also been shown to stimulate the plasma
membrane transport of some intracellularly retained GPCRs
including wild-type α2C-AR and the mutated V2R [90,115,116].
α2C-AR localizes predominantly in the ER and the Golgi with
reduced plasma membrane expression [117]. Enhanced plasma
membrane expression of α2C-AR at low temperature has been
demonstrated to be associated with Raynaud's phenomenon, a
disease characterized by reversible vasospasm of peripheric
vasculature induced by cold or emotional stress. The pathogenic
role of α2C-AR translocation to the plasma membrane in
Raynaud's phenomenon is also supported by the therapeutic
effects of α2-AR antagonists [118]. Indeed, reducing the
temperature from 37 °C to 28 °C induces translocation of α2C-
AR to the cell surface [115,116] and enhances the contractile
response of the rat tail artery to α2-AR agonists [119].
4. Proteins interacting with GPCRs and modulating their
anterograde transport
There are many cellular functions of GPCRs that cannot be
accounted for by the simple model of a lone GPCR activating itsrespective G-protein which in turn modulates down-stream
effectors. Many accessory/chaperone proteins interact with
GPCRs forming multiprotein complexes that may influence
the ligand binding properties of GPCRs, modulate the trafficking
and targeting of GPCRs to their specific subcellular compart-
ments and fine-tune their signaling specificity/efficiency. The
number of GPCR-interacting proteins has grown rapidly in
recent years and identification of GPCR-interacting proteins and
functional studies of the receptor–protein interactions have
proven to be meaningful in elucidating the molecular mechan-
ism of GPCR function [120,121]. Table 2 lists the well-defined
GPCR-interacting proteins which have been demonstrated to be
involved in the regulation of GPCR transport from the ER to the
cell surface. Based on the domains identified in GPCRs which
mediate the interaction of the receptors with binding partners,
these export-related GPCR-interacting proteins can be divided
into three groups. Group I proteins interact with the “magic” C-
termini of GPCRs, group II proteins with the i3 loop and group
III proteins with the N-terminus or without any defined domains
in GPCRs. This chapter will summarize the interaction of
GPCRs with these individual GPCR-interacting proteins and the
functional roles of the interaction in controlling GPCR export.
4.1. Proteins interacting with the C-termini of GPCRs
4.1.1. Homers
The first Homer protein (Homer1a or Ves1) was cloned
from rat hippocampus which has a 120 amino acid enabled/
VASP homology (EVH)-like domain at its N-terminus [122].
In addition to EVH domain, Homer1b, 1c, 2 and 3 proteins
contain a coiled-coil domain at the C-termini. The EVH
domain in the Homer proteins binds to the proline-rich motif
(PPSPFR) in the C-termini of group I metabotropic glutamate
receptors (mGluR1a and 5) and modulate their expression,
localization, and function [123]. Specifically, expression of
Homer1a increases the cell-surface expression of mGluR1a,
but not mGluR5 [124]. Expression of Homer1b causes
retention of the mGluR5 and mGluR1a in the ER and
attenuates their cell-surface expression [125,126]. Interestingly,
Homer1b-induced intracellular retention of mGluR5 can be
released by expression of Homer1a [126]. Furthermore,
transgenic over-expression of Homer1a disrupts mGluR5
binding to Homer1b, suggesting a competitive binding
between Homer1a and Homer1b to the receptor. In contrast
to Homer1a and 1b, the effect of Homer1c on mGluR cell-
surface expression remains controversial. Ciruela et al.
reported that Homer1c increases the cell-surface expression
of mGluR1a [127]. However, Homer1c has also been
demonstrated to reduce the cell-surface localization and
promote the formation of intracellular clusters of mGluR5,
but has no effect on mGluR1 distribution [128].
Interestingly, it has been demonstrated that, in addition to
association with mGluR, Homer is also able to directly bind
Shank, a family of postsynaptic density (PSD) proteins. It has
also been demonstrated that Shank binds to GKAP, a protein
associated with the PSD-95 protein and the NMDA receptor
complex. Therefore, Shank may function as a scaffolding
Table 2
GPCR-interacting proteins that regulate receptor anterograde transport a
Interacting proteins GPCRs Surface
receptor
Binding domains References
Group I: Proteins interacting with the C-termini of GPCRs
Homer1a mGluR1a ↑/No effect PPXXFR [123,124,128]
mGluR5 No effect PPXXFR [123, 128]
Homer1b mGluR5 ↓ ND [125,126]
mGluR1a ↓ ND [125]
Homer1c mGluR1a ↑/No effect PPXXFR [123,127,128]
mGluR5 ↓ ND [128]
GEC1 KOR ↑ C-terminal 35 residues [132]
DRiP78 D1R Dual role FXXXFXXXF [37]
M2-MR ↓ ND [37]
AT1R ↑ YXFXXXXFXXY [133]
ATIP/ATBP50 AT2R ↑ CT [134,135]
Usp4 A2AR ↑ C-terminal 52 residues [136]
gC1q-R α1B-AR ↓ Arginine-rich region [137]
Skb1Hs SSTR1 ↑ CT and NPXXY motif [138]
Tctex-1 Rhodopsin ↑ CT [139]
Protein 4.1G mGluR1a ↑ CT [143]
PTHR ↑ N-terminal 24 residues [144]
Group II: Proteins interacting with the third intracellular loops of GPCRs
Neurofilament-M D1R ↓ i3 loop [142]
Protein 4.1G A1AR ↓ i3 loop [145]
Protein 4.1N D2R ↑ N-portion of i3 loop [146]
D3R ↑ N-portion of i3 loop [146]
Filamin A D2R ↑ N-portion of i3 loop [147,148]
Protachykinin DOR ↑ i3 loop [153]
Group III: Other GPCR interacting proteins
RAMP 1, 2, 3 CRLR ↑ N-terminus [154,155]
RAMP 1, 3 CaSR ↑ ND [162]
NinaA Rhodopsin ↑ ND [163,164]
RanBP2 Opsin ↑ ND [165]
ODR-4 ODR-10 ↑ ND [166]
U131 ↑ ND [167]
HSJ1b Rhodopsin ↓ ND [168]
M10 V2R
pheromone
↑ ND [169]
a ↑, increase; ↓, decrease; ND, not determined; CT, C-terminus; i3, the third intracellular loop.
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mGluR-Homer, forming a signaling complex and modulating
the signaling of both NMDA and mGluR [129,130].
4.1.2. GEC1
GEC1, also named GABAA-receptor associated protein-like
1 and Apg8L, was originally cloned from glandular epithelial
cells as an early estrogen-induced gene. GEC1, together with
GABAA receptor-associated protein (GABARAP), Golgi-
associated 16 kDa ATPase enhancer (GATE16) and light
chain 3 of microtubule-associated protein 1A and 1B, form a
family of microtubule associated proteins. All family proteins
have been demonstrated to be involved in the intracellular
transport processes. For example, GEC1 and GABARAP
interact with the GABAA receptor and microtubules, and
therefore, they may function as linkers between the GABAA
receptor and microtubules modulating the intracellular traffick-
ing and postsynaptic clustering of the GABAA receptor [131].By using multiple approaches including yeast two-hybrid
screening, co-immunoprecipitation and fusion protein pull-
down assay, Liu-Chen's group has successfully demonstrated
that GEC1 directly and specifically interacts with the κ-opioid
receptor subtype (KOR) of the opioid receptors [132]. The
interaction domain was defined to the C-terminal 35 amino
acids of KOR, as truncation of this fragment from the
receptor abolishes GEC1 interaction with the receptor. GEC1
expression facilitates the formation of fully glycosylated
KOR and increases both the total and cell-surface expression
of KOR. In contrast, expression of GEC1 does not signi-
ficantly affect receptor ligand binding affinity, coupling to G
proteins, or agonist-induced internalization. In addition to
KOR, GEC1 also interacts with tubulin and N-ethylma-
leimide-sensitive factor, which have both been demonstrated
to be involved in protein trafficking. These data indicate
that GEC1 modulates KOR trafficking in the biosynthesis
pathway.
862 C. Dong et al. / Biochimica et Biophysica Acta 1768 (2007) 853–8704.1.3. DRiP78
Bermak et al. identified DRiP78, a protein with molecular
mass of 78 kDa that interacts with D1R [37]. The interaction is
mediated through the receptor C-terminal F(X)3F(X)3F motif as
discussed in the Section 2.1.2. DRiP78 was then demonstrated
to be an ER-membrane associated chaperone protein belonging
to the DnaJ/Hsp40 class. DRiP78 appears to play a dual role in
regulating the anterograde transport of D1R. Coexpression of
DRiP78 with D1R induces intracellular redistribution of the
receptor to the ER and reduces its transport to the cell-surface as
measured by ligand binding. Interestingly, disruption of the
interaction between DRiP78 and D1R by synthesized C-
terminal peptides also significantly reduces the cell-surface
expression of the receptor. These data indicate that a strictly
moderate endogenous level of DRiP78 is essential for efficient
export of D1R from the ER.
In addition to D1R, export trafficking of other GPCRs is also
regulated by DRiP78 [37,133]. Interestingly, expression of
DRiP78 induces opposite effects on the transport of M2-MR and
AT1R. Similar to D1R, the cell-surface expression of M2-MR is
attenuated by over-expression of DRiP78. In contrast, DRiP78
expression facilitates the plasma membrane expression of AT1R
[133].
4.1.4. ATIP1/ATBP50
ATIP1 (AT2R-interacting protein) was identified to directly
interact with angiotensin II type 2 receptor (AT2R) in a yeast two-
hybrid system using the C-terminus of AT2R as bait [134].
The interaction between ATIP1 and AT2R is highly specific as
ATIP1 does not interact with the C-termini of other GPCRs
including AT1R, β2-AR and bradykinin type 2 receptor (B2R).
ATIP1 is suggested to function as a signaling component in the
pathway of AT2R-mediated growth inhibition, as it cooperates
with AT2R to trans-inactivate receptor tyrosine kinases and in-
hibits cell growth. Using a similar strategy, Wruck et al. identified
a 50 kDa Golgi membrane-associated protein interacting with the
C-terminus of AT2R, and thus named it as ATBP50 [135], which
is identical to ATIP1. Further studies showed that downregulation
of ATBP50 by siRNA induces an accumulation of AT2R in
intracellular compartments and reduces AT2R transport to the
plasma membrane in N1E-115 cells, indicating that ATBP50 is
necessary for the cell-surface expression of AT2R.
4.1.5. Usp4
Usp4 is a deubiquitinating enzyme, which binds to the
C-terminus of A2AR [136]. Over-expression of Usp4 promotes
the transport of A2AR from an intracellular localization to the
cell surface. This effect is probably mediated by a reduced level
of receptor ubiquitination, which prevents receptors from being
targeted for degradation. These findings reveal a novel function
of a deubiquitinating enzyme to rescue receptors from ERAD,
thereby increasing the cell-surface expression of otherwise
functionally active receptors.
4.1.6. gC1q-R
gC1q-R (p33, hyaluronan-binding protein) was originally
identified as a complement regulatory molecule that binds to theglobular heads of C1q. In addition to C1q, gC1q-R binds a
variety of plasma proteins including thrombin, vitronectin,
fibrinogen, and high molecular weight kininogen and patho-
genic microorganisms such as HIV Rev and HIV-1tat. By using
yeast two-hybrid screening and co-immunoprecipitation tech-
niques, Xu et al. demonstrated that gC1q-R interacts with α1B-
AR through an arginine-rich sequence in the C-terminus of the
receptor. Increased expression of gC1q-R traps α1B-AR in the
intracellular compartments and attenuates the cell-surface
expression of α1B-AR [137].
4.1.7. Skb1Hs
Using the C-terminal tail of somatostatin receptor subtype
1 (SSTR1) as bait in yeast two-hybrid screening, Schwarzler
et al. identified the human Skb1 sequence (Skb1Hs) as a
SSTR1 interacting protein [138], which is homologous to the
yeast protein Skb1, known to down-regulate mitosis. The
interaction requires the entire C-terminus and the NPXXY
motif in the seventh transmembrane domain of SSTR1 and
the N-terminus and the S-adenosylmethionine binding
domain of Skb1Hs. Skb1Hs forms clusters or aggregates
without resembling any known intracellular structures as re-
vealed by confocal microscopic analysis. However, a certain
portion of Skb1Hs co-localizes with SSTR1 at the plasma
membrane when co-expressed with SSTR1. Moreover, co-
expression of Skb1Hs with SSTR1 dramatically increases
somatostatin binding. These data suggest that Skb1Hs may
function as a chaperone to correctly target SSTR1 to the cell
surface.
4.1.8. Tctex-1
Tctex-1 (the t-complex testis-expressed 1), a cytoplasmic
light chain of dynein, has been demonstrated to interact directly
with the C-terminal tail of rhodopsin [139]. This interaction
provides an important linkage between the receptor-carrying
vesicles and the microtubules, which may be responsible for the
microtubule-based transport and vectorial targeting of rhodop-
sin. Interestingly, Lanier's group has recently demonstrated that
AGS2 (activator of G protein signaling 2), which is identical to
Tctex-1, interacts preferably with βγ subunits and modulates
heterotrimeric G protein activation independent of GPCRs
[140,141].
4.2. Proteins interacting with the third intracellular loops of
GPCRs
4.2.1. Neurofilament-M
Neurofilaments are major components of the cytoskeleton in
neurons and play an essential role in axonal transport.
Neurofilament-M (NF-M) is a subunit of neurofilaments and
has been demonstrated to specifically interact with the i3 loop of
D1R [142]. This interaction prompts intracellular accumulation
of DOR, reduces the cell-surface expression of the receptor, and
attenuates D1R-mediated cAMP accumulation. Therefore, the
interaction between NF-M and D1R may be responsible for the
axonal transport of D1R to specific subcellular neuronal
locations.
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The cytoskeletal protein 4.1 family includes the prototypic
protein 4.1 R (red-blood-cell-type) and its homologues 4.1B,
4.1G, 4.1N, and 4.1O. These proteins form multimolecular
complexes with transmembrane or membrane-associated pro-
teins to provide structural support to the cell membrane and
regulate signal transduction. Some of the 4.1 family proteins
have been demonstrated to interact with GPCRs and regulate
the cell-surface expression of the receptors. For example,
protein 4.1G interacts with the C-termini of mGluR1a and PTH/
PTH-related protein receptor (PTHR) resulting in an increase in
the cell-surface expression of the receptors [143,144]. Interest-
ingly, protein 4.1G interaction with the i3 loop of A1AR
reduces receptor expression at the cell surface [145]. In contrast
to protein 4.1G which has opposing effects on the cell-surface
targeting of different GPCRs, protein 4.1N interacts with
dopamine D2 and D3 receptors (D2R and D3R) to facilitate
their transport to the cell surface [146]. The binding sites have
been mapped to the N-terminal portion of the i3 loop of D2R
and D3R and the C-terminal domain of protein 4.1N. These data
indicate that the interaction of 4.1 proteins with distinct GPCRs
may play an important role for targeting to or stabilizing of the
receptors at the cell surface.
4.2.3. Filament A
Filament A (ABP-280), an actin-binding protein, has been
shown to be able to interact with several GPCRs including D2R
and D3R [147–149]. The interaction domain is localized to the
C-terminal portion of the i3 loop of D2R and to both the N- and
C-terminal portions of the i3 loop of D3R [147]. Mutation of
serine residue at position 358 to aspartic acid in the filamin A-
association domain to mimic the effects of receptor phosphor-
ylation or direct activation of PKC by PMA treatment similarly
compromises the binding of the receptor to filamin A,
suggesting that PKC-mediated phosphorylation of D2R plays
an important role in regulating its interaction with filamin A
[148]. Lin et al. demonstrated that D2R expresses at the plasma
membrane in filamin A-containing A7 cells but displays a
predominantly intracellular distribution in filamin A-deficient
M2 cells, indicating that filamin A may be required for the
correct targeting of D2R to the plasma membrane [147].
However, other data suggest the interaction with filament A is
required for D2R clustering on the plasma membrane [148]. In
addition to dopamine receptors, filament A also interacts with
the C-termini of μ-opioid (MOR), calcitonin (CTR) and
calcium-sensing receptors (CaSR) and the interaction is
involved in the regulation of internalization and/or recycling
of the receptors [149–152].
4.2.4. Protachykinin
Protachykinin is the precursor of the neuropeptide substance
P in the large dense-core vesicles (LDCVs) of small dorsal root
ganglion neurons. Guan et al. found that the substance P domain
of protachykinin interacts directly with the i3 loop of DOR
[153]. The interaction between DOR and protachykinin
mediates the sorting of DOR into LDCVs and regulates the
cell-surface expression of DOR in pain-sensing neurons. Theinteraction may play an important role in the stimulus-induced
plasma membrane insertion of DOR in small dorsal root
ganglion neurons and DOR-mediated spinal analgesia.
4.3. Other GPCR-interacting proteins
4.3.1. RAMPs
Receptor activity-modifying proteins (RAMPs) are a group
of single transmembrane proteins including RAMP1, RAMP2
and RAMP3, the discovery of which has revealed a new era for
studying the pharmacology of GPCRs. RAMPs directly interact
with GPCRs, which not only assists trafficking and folding of
GPCRs in the intracellular compartments but also more
importantly defines phenotypes of the receptors at the plasma
membrane. RAMPs were originally found to form complex
with the calcitonin receptor-like receptor (CRLR), assisting its
export trafficking and altering receptor responses to its ligands
[154]. RAMP1 interacts with CRLR and facilitates its transport
from the ER to the plasma membrane yielding a high affinity
calcitonin gene-related peptide receptor (CGRPR), whereas
RAMP2/3 transport CRLR to the cell surface generating
receptors specific for adrenomedulin [154,155]. Similarly,
heterodimerization of RAMPs with CTR dictates the pheno-
types of receptor for amylin [156,157]. The long extracellular
N-terminal portion of RAMPs has been demonstrated to contain
crucial information responsible for defining different receptor
phenotypes as well as mediating their interaction with the
receptors [158,159]. The transmembrane domain of RAMP1 is
also essential for functional expression of CGRPR at the plasma
membrane. In contrast, the shorter C-terminal domain of
RAMP1 contains a retention motif, QSKRT, responsible for
its intracellular retention in the absence of receptor [160].
Several other class II GPCRs have also been demonstrated to
interact with different RAMPs. The vasoactive intestinal
polypeptide/pituitary adenylate cyclase-activating peptide
receptor interacts with all three RAMPs. The glucagon and
parathyroid hormone 1 receptors interact with RAMP2 and the
parathyroid hormone 2 receptor interacts with RAMP3 [161].
However, none of these interactions have been shown to be a
prerequisite for receptor transport to the plasma membrane. On
the other hand, the transport and maturation of CaSR, a member
of class III GPCRs, requires RAMP co-expression. RAMP1 and
3, but not RAMP2, is sufficient for targeting CaSR to the
plasma membrane [162]. This is consistent with the chaperone
function of RAMPs observed in the calcitonin receptor family
and suggests that the failure to transport to the plasma
membrane of a number of GPCRs when expressed hetero-
logously may be due to the insufficient expression of their
specific chaperone proteins, like RAMPs.
4.3.2. NinaA
The cyclophilin homolog ninaA in Drosophila is required
for rhodopsin Rh1 export from the ER and transport through the
secretory pathway [163]. Mutation of ninaA retains Rh1 inside
the ER and prevents its trafficking to the microvillar membrane.
In addition, NinaA was demonstrated to form a complex with
Rh1 and co-localize with Rh1 in secretory vesicles [164]. These
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escorting Rh1 along the biosynthetic pathway.
4.3.3. RanBP2
RanBP2, a cyclophilin-related protein, was identified to act
as a chaperone for the red/green opsin in mammalian
photoreceptor cells [165]. RanBP2 contains two contiguous
domains, Ran-binding domain (RBP4) and cyclophilin. Cyclo-
philin modulates the opsin by its peptide prolyl cis-trans
isomerization activity to stabilize the interaction between RBP4
and opsin. Therefore, RanBP2 may be involved in the
biosynthesis of opsin in photoreceptor cells.
4.3.4. ODR-4
The C. elegans ODR-4, expressed exclusively on the
intracellular membrane of chemosensory neurons, is required
for the proper targeting of chemosensory receptor ODR-10 to
olfactory cilia [166]. ODR-4 is also able to facilitate the
trafficking of receptors in mammalian cells. The surface
expression of rat olfactory U131 is increased by ODR-4 in
both olfactory odora cells and Chinese hamster ovary cells
[167]. ODR-4 may act as a chaperone during receptor folding or
transport along the secretory pathway.
4.3.5. HSJ1
HSJ1 is a cytosolic heat shock protein belonging to the type
II DnaJ/Hsp40 family and has two isoforms HSJ1a and HSJ1b.
Both isoforms can regulate the ATPase activity and substrate
binding of Hsp70. HSJ1b has been shown to interact with
rhodopsin by co-immunoprecipitation [168]. Expression of
HSJ1b arrests rhodopsin in the ER and increases the formation
of rhodopsin inclusion in neuroblastoma cells, which is
dependent on the prenylation-mediated targeting of HSJ1b to
the cytoplasmic face of the ER, but independent on the function
of Hsp70. These data indicate that, in addition to the ER
chaperone proteins, cytoplasmic chaperones may also be able to
modulate the processing and targeting of GPCRs.
4.3.6. M10 molecules
The M10 family proteins belong to the major histocompat-
ibility complex class Ib. Loconto et al. demonstrated that V2R
pheromone receptor co-expresses with the M10 family
members and interacts with the M10.7 protein and β2-
microglobulin forming a multimolecular complex in neurons
[169]. The M10 protein appears essential for targeting the V2R
pheromone receptor to the cell surface and functions as an
escort protein for the V2R pheromone receptor traffic to the cell
surface. Such a specific association between the V2R
pheromone receptor and the M10 protein in neurons may
provide novel mechanisms underlying pheromone recognition.
5. Pathways that mediate GPCR transport from the ER
through the Golgi to the cell surface—identification by
studying the function of small GTPase Rab1
Rab GTPases are the largest branch of the Ras-related
GTPase superfamily, consisting of more than 60 members inmammals and 11 in yeast, each with a distinct subcellular
localization pattern that correlates with the compartments
between which they coordinate transport. The first identified
function of mammalian Rab proteins was the regulation of Rab5
in early endosome fusion. It is now well established that Rab
GTPases are involved in almost every step of vesicle-mediated
protein transport, particularly the targeting, tethering, and fusion
of transport vesicles with the appropriate acceptor membrane
[170]. Rab function in vesicle trafficking is largely mediated
through its ability to undergo GTP/GDP exchange and GTP
hydrolysis, which are highly regulated by association with
accessory proteins including GDP dissociation inhibitors
(GDIs), guanine nucleotide exchange factors (GEFs) and
GTPase activating proteins (GAPs). The inactive, GDP-bound
conformation of Rab proteins is maintained in the cytosol
through association with GDIs, which function as chaperones
mediating Rab protein translocation from the cytosol to the
membrane. Membrane-associated GDP-bound Rab–GDI com-
plexes undergo GDP exchange for GTP, which is accelerated by
GEFs. GTP-bound Rab proteins recruit their effectors and
coordinate the migration, docking, and fusion of transport
vesicles to acceptor membrane. Since intrinsic GTPase activity
of Rab proteins is very low, GTP hydrolysis to GDP of Rabs is
stimulated by GAPs [170]. A characteristic of Rabs is that the
GTP/GDP exchange cycle of Rabs superimposes with their
association with and dissociation from subcellular organelle
membranes.
After export from the ER, GPCRs are transported in vesicles to
the cell surface through the ERGIC, the Golgi (cis-, medial and
trans-Golgi) and the TGN. Elucidation of the roles for Rab
GTPases in GPCR trafficking have mainly been focused on the
events involved in internalization and degradation of the receptors
[171,172]. Whereas Rab4 [173–176] and Rab11 [173,175,177–
180] are mainly involved in the recycling of internalized receptor
from the endosome back to the plasmamembrane, Rab5 regulates
the internalization of GPCRs from the plasma membrane to the
endosome [173,175,176,178,179,181–184] and Rab7 partici-
pates in the process of targeting receptors to the lysosome for
degradation [178,179,182,185]. Interestingly, AT1R is able to
directly interact with Rab5 via its C-terminus and the interaction
is important for the fusion of endocytic vesicles [179]. These
observations suggest that GPCR trafficking may be controlled
through their physical association with the transport machinery.
In contrast to the relative well characterized functions of Rab
GTPases involved in endocytosis, much less is known about the
involvement of Rab proteins in GPCR export. Our laboratory
has focused on understanding the role of Rab1 in the export
trafficking of GPCRs [186–188]. Rab1 is one of the most
extensively studied and best understood Rab GTPases. There
are two isoforms, Rab1a and Rab1b, with >90% identity in their
amino acid sequences. Rab1 is specifically localized in the ER
and the Golgi apparatus and regulates anterograde transport
from the ER to and through the Golgi of proteins including
VSVG, low-density lipoprotein receptor, β-amyloid precursor
protein and CFTR. Interestingly, Rab1 regulates CFTR
transport from the ER to the cell surface in a cell-type specific
fashion. CFTR transport to the cell surface is dependent on
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BHK and CHO cells [189].
We first determined the role of Rab1 in the transport from the
ER through the Golgi to the cell surface of AT1R, β2-AR and
α2B-AR [186]. Our data demonstrated that attenuation of Rab1
function by expressing dominant-negative Rab1 mutants or
siRNA-mediated depletion of endogenous Rab1 significantly
inhibits the cell-surface expression of AT1R and β2-AR.
Consistent with Rab1 function in regulating protein transport
from the ER to the Golgi, receptors accumulate in the ER and
the Golgi apparatus. In contrast, dominant-negative Rab1
mutants and Rab1 siRNA have no effect on the cell-surface
targeting and subcellular distribution of α2B-AR [186]. These
data indicate that export trafficking of distinct GPCRs can be
differentially modulated by Rab1 GTPase. More importantly,
these data demonstrate that different GPCRs may use distinct
pathways for their transport from the ER through the Golgi to
the cell surface. In particular α2B-AR export is mediated
through a non-conventional, Rab1-independent pathway.
We then determined whether the modification of Rab1-
mediated ER-to-Golgi transport could alter the cell-surface
expression of endogenous AT1R, β-AR and α1-AR [187,188].
Adenovirus-mediated gene transfer of the dominant-negative
mutant Rab1N124I significantly inhibits cell-surface expression
of endogenous AT1R, β1-AR, β2-AR, α1A-AR and α1B-AR in
primary cultures of neonatal rat ventricular myocytes, indicating
their cell-surface targeting is mediated through a Rab1-
dependent pathway. More interestingly, augmentation of Rab1
function by adenoviral expression of Rab1 markedly increases
the cell-surface expression of AT1R, α1A-AR and α1B-AR, but
not β1-AR and β2-AR. These data suggest that endogenous
Rab1 is a rate-limiting factor for transport from the ER to the
cell surface of AT1R, α1A-AR and α1B-AR, but not β1-AR and
β2-AR. These data also provide strong evidences implicating
ER-to-Golgi transport as a regulatory site for selective control
of GPCR targeting to the cell surface.
We have demonstrated that α2B-AR, AT1R [29], β2-AR and
α1B-AR utilize the same F(X)6LL motif for export from the ER,
suggesting that their export from the ER is directed by the same
motif-mediated mechanism and may be sorted from other
GPCRs with different ER exit motifs. Despite their use of the
same ER export motif, there is a difference in Rab1 dependency
among these GPCRs [186–188]. Thus the sorting of receptors
into Rab1-regulated transport pathways does not occur at the
level at which this ER export motif functions. The F(X)6LL
motif controls receptor export from the ER, whereas Rab1
coordinates receptor transport to the Golgi after exit from the
ER. These data strongly indicate that selective control of GPCR
transport from the ER to the cell surface may be implemented at
multiple transport steps.
6. Modulation of GPCR signaling by the components of
transport machinery
The magnitude of GPCR signaling is determined by the level
of receptor at the plasma membrane available for binding to
their agonists. Manipulation of receptor export to alter thereceptor cell-surface expression level will eventually influence
receptor signaling. Our studies have demonstrated that
manipulation of components of the transport machinery in the
ER-to-Golgi transport selectively influences the signaling of the
receptors [186–188]. These studies were first performed on
exogenous receptors in HEK293T cells and then expanded to
endogenous receptors in primary cultures of neonatal ventri-
cular myocytes. The effects of manipulating the ER-to-Golgi
transport of GPCRs on the agonist-mediated signaling are
consistent with those on the cell-surface targeting of the
receptors. In HEK293 cells, dominant-negative Rab1 mutants
and siRNA-mediated depletion of Rab1 significantly attenuate
AT1R-mediated inositol phosphate accumulation and ERK1/2
activation and β2-AR-mediated ERK1/2 activation, but not
α2B-AR-stimulated ERK1/2 activation. In cardiac myocytes,
adenovirus-mediated expression of Rab1N124I markedly
attenuates ERK1/2 activation and hypertrophic growth as
measured by protein synthesis, cell size, and sarcomeric
organization in response to stimulation with the GPCR agonists,
angiotensin II, isoproterenol and phenylephrine. More interest-
ingly, increasing Rab1 function by adenovirus-mediated gene
transfer of wild-type Rab1 selectively augments ERK1/2
activation and myocyte hypertrophic response to angiotensin
II and phenylephrine, but not isoproterenol. These data strongly
indicate that GPCR function can be selectively or differentially
modulated through manipulating GPCR traffic from the ER to
the Golgi and implicate the ER-to-Golgi transport as a
regulatory site for control of cardiomyocyte growth. Therefore,
defining the functional role of individual Rab GTPases in
cardiomyocyte growth by modifying the transport of selective
GPCRs may provide a novel foundation for the development of
strategies in treating cardiac disease.
Over-expression of the components of transport machinery
may provide a novel means for facilitating the targeting of
GPCRs to the cell surface. This is also strongly supported by
our recent studies on the function of Rab4 GTPase in regulating
the recycling of endogenous β-AR in cardiac myocytes [174].
We demonstrated that increased wild-type Rab4 expression
facilitates recycling to the plasma membrane and signaling of β-
AR in cultured cardiac myocytes and transgenic mouse hearts,
indicating a novel way to increase endogenous β-AR function.
Most importantly, over-expression of Rab4 induces physiolo-
gical cardiac hypertrophy without clear functional deterioration
[174], suggesting that modifying the function of the compo-
nents of vesicular transport machinery (e.g. Rab4 GTPase) has
therapeutic potential as an alternative strategy to enhance
receptor signaling and possibly improve myocardial function in
heart failure.
7. Conclusion
The physiological functions of GPCRs are dependent on
their export trafficking and precise localization in the cell.
Indeed, defective GPCR transport from the ER to the cell
surface is associated with the pathogenesis of a variety of
human diseases. The achievements reviewed above have greatly
advanced our understanding of GPCR export along the
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Overall, these studies indicate that GPCR export from the ER
and transport to the Golgi and the cell surface is a highly
regulated, dynamic process. However, the players involved in
the ER-Golgi-cell surface transport of GPCRs have just begun
to be revealed. Further elucidation of the regulatory mechanism
underlying GPCR export trafficking may provide an important
foundation for developing new therapeutic strategies in treating
diseases.
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